#Diphtheria and Pertussis and Tetanus (DTP) Vaccine Market Growth

[mitalipingale]

https://carbonfacesocial.org/blogs/86251/Diphtheria-Pertussis-and-Tetanus-DTP-Vaccine-Market-Analysis-Size-Share

The Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is expected to reach US$ 8.67 billion by 2031 at a CAGR of 5.30%.

[researchnesterinsights]

Cell Bag Bioreactor Chamber Market By New Business Developments, Innovations, And Top Companies – Forecast To 2027

The report titled “Cell Bag Bioreactor Chamber Market Outlook: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the global cell bag bioreactor chamber market in terms of market segmentation by application, by scale, by end user and by region.

The recent growing requirement for bioreactors used in various applications, for instance, tissue engineering, cell expansion and 3D tissue construction coupled with reasonable price backing and decent return on investment are anticipated to increase the demand for cell bag bioreactors during the forecast period, i.e., 2019-2027. The overall expansion of healthcare industry with growing need for controllable environmental conditions such as pH, temperature, shear stress and nutrient supply for cellular constructs coupled with continuous research and developments in order to provide medicines and remedies for autoimmune disorders, organ rejections, cancer and others is anticipated to further drive the market growth.

The global cell bag bioreactor chamber market is segmented by application, by scale and by end user. On the basis of application, the market is further segmented into antibody production, virus production, CGMP production, insect cell production, vaccines and others, out of which the vaccines segment is anticipated t0 dominate the market share on the back of recent developments in mammalian cell culture techniques and emergence of new diseases and disorders, for instance, West Nile virus, pathogenic diseases, influenza and others. As per the data by UNICEF, about 116 million children were immunized against diphtheria, tetanus and pertussis (DTP) in 2018. Additionally, the growing inclination of vaccine industry towards cell based technology is estimated to affect market positively.

Geographically, the markets in North America and Europe are anticipated to hold the leading share in the cell bag bioreactor chamber market on account of highly developed healthcare industry and growing research and development activities in the region. The market in Asia-Pacific is anticipated to witness growing share in the market on the back of untapped market and increasing pharmaceutical companies along with recent shift towards automatic systems from the traditional methods, for instance, monoclonal antibiotics and cell culturing.

New Developments and Innovations to Boost the Demand for Cell Bag Bioreactor Chambers in Future

The development of various new bioreactors with improved features and technological advancements coupled with increase in usage of hybrid bioreactor technology aimed at effective waste management is anticipated to further accelerate the market growth. Moreover, with increase in demand for better healthcare facilities, companies are providing better solutions for cell development, clinical trial manufacturing and process development.

Request Sample of This Strategic Report @ https://www.researchnester.com/sample-request-851

Industry Players are Progressing towards Minimizing the Barriers faced by the Cell Bag Bioreactor Chamber Market

The high cost, problems related to contamination and sterility and issues related to automating the culture process coupled with volumetric productivity involved in use of cell bag bioreactors are estimated to hinder the market growth. Additionally, stringent rules & regulations related to approval of these products are major restraining factors in the growth of cell bag bio reactor chamber market during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global cell bag bioreactors chamber market which includes company profiling of GE healthcare (GE), Merck Millipore (MRK), Thermo Fisher Scientific Inc. (TMO), Startorious Stedim Biotech SA. (DIM), Pall Corporation, Celltainer, Finesse, Kühner AG, TERUMO BCT, INC. and Applikon Biotechnology. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global cell bag bioreactor chamber market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Request a Sample Copy of Concerned Market Report @ https://www.researchnester.com/sample-request-851

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact Us

AJ Daniel Email: info@researchnester.com U.S. Phone: [+1 646 586 9123] U.K. Phone: [+44 203 608 591]

Research Nester

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

 Leave a Reply 

[healthcare-market]

Vaccine Market Opportunity Assessment and Forecast up to 2025

The evolution of the vaccines market has increasingly pivoted on enormous advances in science of adjuvants over the past several decades. The strides in human vaccine development especially have been fuelled by ceaseless advances in virology, molecular biology, and immunology.

New immunization routes have been discovered and massive inoculation drives have been supported by governments around the world. With robust support from public health systems in several countries, continued immunization programs have been stridently useful in disease prevention.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=21

The robust long-lasting immunity built on by vaccines has been the major underpinning for their role in preventing a range of diseases. These include diphtheria, pertussis, tetanus, measles, poliomyelitis, rubella, smallpox, sepsis, pneumococcal pneumonia, meningitis, hepatitis B, varicella-zoster, cholera, and tuberculosis. This has made investments in the vaccine market worthwhile in improving the health and wellbeing of humanity. Some of the most lethal conditions for which vaccines have been effective in reducing the burden are malaria, HIV-1, and Mycobacterium tuberculosis (MTB).

The report by TMR see the vaccine market to see substantial revenue potential during the forecast period of 2017 – 2025. The study projects the valuation to climb to 48.0 Bn by 2025.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21

Role of Vaccines in Preventing Numerous Childhood Diseases Makes Prospects in Vaccine Market Bright

Recommendations for immunization programs cover both adults and children. Stridently, national healthcare systems in various countries have specific vaccination recommendations in place for newborns and children. Key vaccines administered to polio, meningococcal disease, DTP, and pneumococcal disease. The implementation of recommendations by the medical and the healthcare industries has been on account of the established role of vaccines in preventing multiple viral and bacterial infections. The trend is expected to underpin lucrative gains to players in the global vaccine market.

Recommendations for adult vaccination have also picked up pace, fueling the value chain of players in the vaccine market. Of note, adults who weren’t able to receive certain vaccinations in childhood have become eligible candidates, notably bolstering the demand for vaccines measles, mumps, rubella, and varicella.

Request for Analysis of COVID19 Impact on Vaccines Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=21

R&D for New Mechanisms of Action to Boost Outcomes Expands Vaccine Market Avenue

Advances made in adjuvant system have been a prominent pillar for new array of products in the vaccine market. The number of licensed adjuvants for human vaccine development has risen over the past few years. Global heavyweights in the vaccine market are keenly testing new line of adjuvant systems in clinical trials to tap into the market possibilities, notes a study on the vaccine market. Particularly for the currently emerging Covid-19, a number of adjuvant systems in various phases of clinical trials have been tested for SARS-CoV-2 vaccines, and are in different clinical stages including in Phase 3 trials. Notable examples include Advax and Matrix M. With vaccine developers across the world scrambling to launch vaccines with long-term immunity against SARS-CoV-2, the trend will confer on them incremental opportunities throughout the forecast period. A wide range of vaccine types are under investigation, and the lucrativeness of the pipeline is evident in the emerging demand for booster doses in some countries, such as the U.S.

On the other hand, vast immunization drives in recent months notably in emerging economies has spurred the growth of the vaccine market. This has opened floodgates of opportunities for vaccine research in Asia Pacific.

In low and middle-income countries, such as in the Middle East and Africa, a number of vaccine candidates are being tested for malaria and other debilitating infections. Aside from this, vaccine developers are likely to focus on tropical diseases. On the other hand, T cell vaccines show a promising potential, opening new vistas in vaccine market.

In the coming years, the push for establishing and maintaining herd immunity is a key trend that will greatly influence the contours of the vaccine market.

Buy now Vaccines Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=21&ltype=S

The review is based on TMR’s report titled, “Vaccines Market (Vaccine Type - Inactivated, Live Attenuated, Toxoid, Conjugate; Valance - Monovalent, Multivalent; Route of Administration - Oral, Injectable; Indication - Influenza, Hepatitis, Polio, Meningococcal Disease, Pneumococcal Disease, DTP, Rotavirus, MMR, Human Papilloma Virus; Distribution Channel - Institutional Sales, Hospital Pharmacies, Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025”.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/rising-patient-pool-and-increasing-healthcare-expenditure-to-invite-favorable-growth-prospects-for-gout-therapeutic-market-during-2019-2027-tmr-301177001.html

https://www.prnewswire.co.uk/news-releases/generic-injectables-market-to-exceed-us-307-bn-value-by-2031-players-focus-on-increasing-patient-compliance-and-new-product-launches-states-tmr-report-829478758.html

https://www.prnewswire.com/news-releases/growing-cases-of-spinal-disorders-to-pain-strokes-of-growth-across-bone-graft-substitutes-market-between-2020-and-2030-tmr-301182424.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY – 12207

United States

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.co

[marketresearchhealthcarefuture]

HUMAN VACCINES MARKET 2021 SIZE, SHARE, ANALYSIS, GROWTH, GLOBAL INDUSTRY OVERVIEW AND FORECAST

A vaccine contains a biological preparation of a weakened or killed microbial agent, its toxins or its surface proteins, which provides active acquired immunity against the disease caused by the microbe. Vaccination stimulates and trains the body immunity to recognize and destroy the microbial threat in later encounters. According to World Health Organization (WHO), out of the total number of children worldwide who did not receive the required three doses of diphtheria-tetanus-pertussis vaccines, more than 40% were from sub-Saharan Africa. Sub Saharan Africa accounts for a bulk share of unimmunized people in Africa. The other African nations with large number of unimmunized people include Nigeria, Iraq, Chad, Niger, Angola, Somalia, Sudan, Democratic Republic of Congo, Ethiopia, Iraq, Nigeria, Uganda and South Africa.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/2671

The market for vaccines in Middle East and Africa presents immense potential. The market driving factors are unmet needs for vaccination, policies of national Governments and international bodies such as World Health Organization (WHO) which provide huge funding and international aid, increasing funds from philanthropy organizations such as Bill and Melinda Gates Foundation, inclusion of several new vaccines in the national immunization schedule of many countries, development of new vaccines such as for hepatitis; growing awareness, growth of low cost vaccine manufacturing especially in developing countries, the entry of China in the vaccine market etc.

Key PlayersThe major participants of this market are: GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others

.Regional Analysis:Depending on geographic region, human vaccine market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs and the favorable government policies.Segmentation:Middle East and Africa human vaccines market has been segmented on the basis of technology commonly mentioned as “by technology” which comprises attenuated, inactivated, toxoid, conjugate, & subunit, recombinant DNA. On the basis of disease indication the market is segmented into pneumococcal, influenza, hepatitis, rotavirus, DTP, polio and others. On the basis of type market is segmented into prophylactic and therapeutic. On the basis of composition the market is again segmented into mono vaccine and combination vaccines. On the basis of route of administration; market is segmented into oral, injectable and other. On the basis of end user; market is segmented into children and adults.

Browse full Human Vaccines Market @ https://www.marketresearchfuture.com/reports/human-vaccines-market-2671

Taste the market data and market information presented in more than 60 market data tables and figures spread over 84 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “The Middle East and Africa Human Vaccine Market Research Report - Forecast to 2022”.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

[shruticmi]

The Global Conjugate Vaccine Market to surpass at US$ 12,977.2 million in 2018.

Summary:The Global Conjugate Vaccine Market expected to reach for a CAGR of 9.6% during 2018–2026.

Market Overview:

Conjugate vaccines are used to create a more powerful, combined immune response from infectious diseases.The vaccines currently in use for children against pneumococcal bacterial infections are made using this technique.

The factors fuelling the growth of The Conjugate Vaccine Market includes the increasing demand of meningococcal vaccines and pneumococcal.

For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077

Download the PDF Brochure on The Global Conjugate Vaccine Market here

Key Trend:

Due increasing prevalence of meningococcal infections resulted as expected to aid in growth of the global conjugate vaccine market.

Rising use of conjugate vaccines for adults, huge number of regulatory approvals for conjugate vaccines,growth in prevalence of diseases caused by microorganisms such as Streptococcus pneumoniae and Neisseria meningitidis, and technological advancements major drivers the growth of the market.

Competitive Landscape

Key players operating in the global conjugate vaccine market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med

Market Segmentation:

By Type

·   Monovalent Conjugate Vaccines

·   Multivalent Conjugate Vaccines

By Disease Indication

·   Pneumococcal

·   Influenza

·   Diphtheria Tetanus and Pertussis (DTP)

·   Meningococcal

·   Others

By Pathogen Type

·   Bacterial Conjugate Vaccine

·   Viral Conjugate Vaccine

·   Combination (Viral and Bacterial) Conjugate Vaccine

By End User

·   Pediatrics

·   Adults

Buy Now the Research Report on The Global Conjugate Vaccine Market

Related Topics:

Healthcare Contract Research Outsourcing Market Analaysis

Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices. Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

North America Wound Debridement Products Market Analysis

Increasing diseases in North America are particularly ulcers attributed to either diabetes, venous disease, or arterial disease has been observed to be major factor for the market growth. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. 

Phone: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Reference:

Coherent Market insight

[mitalipingale]

The Diphtheria, Pertussis and Tetanus (DTP) Vaccine Market is expected to reach US$ 8.67 billion by 2031 at a CAGR of 5.30%.

[kdmarketresearch]

Conjugate Vaccines Market  to Observe Strong Development by 2022

As per the research conducted by KD Market research, the report titled “ Conjugate Vaccines Market (2019 - 2022)” provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Conjugate Vaccines Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.

The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.

Request for sample Copy@ https://www.kdmarketresearch.com/sample/3138

Disease indication segment insights:

Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017–2022.

End user segment insights:

The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.

Regional insights:

Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the region’s widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.

Companies covered: 1. GlaxoSmithKline 2. Pfizer Inc. 3. Merck & Co. 4. Novartis 5. Sanofi Pasteur 6. CSL Limited 7. Bharat Biotech International 8. Biological E Limited 9. Serum Institute of India

Access Complete Research Report with toc@ https://www.kdmarketresearch.com/report/3138/global-conjugate-vaccines-market-2019-2022

Table of Content

Chapter 1. Executive summary

1.1. Market scope and segmentation 1.2. Key questions answered 1.3. Executive summary

Chapter 2. Global conjugate vaccine market – overview

2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis 2.2. Market drivers 2.3. Market trends 2.4. Market challenges 2.5. Value chain analysis 2.6. Porter's five forces analysis 2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 3. North America conjugate vaccine market

3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 4. Europe conjugate vaccine market

4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 5. Asia-Pacific conjugate vaccine market

5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 6. Latin America conjugate vaccine market

6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 7. The Middle East and Africa conjugate vaccine market

7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 8. Competitive landscape

8.1. GlaxoSmithKline 8.1.a. Company snapshot 8.1.b. Products/services 8.1.c. Major initiatives/highlights 8.1.d. Growth strategy 8.1.e. Geographical presence 8.1.f. Key numbers Note: Similar information areas will be covered for the remaining competitors: 8.2. Pfizer Inc. 8.3. Merck & Co. 8.4. Novartis 8.5. Sanofi Pasteur 8.6. CSL Limited 8.7. Bharat Biotech International 8.8. Biological E Limited 8.9. Serum Institute of India

Chapter 9. Conclusion 9.1. Future outlook

Appendix 1. List of tables 2. Research methodology 3. Assumptions

Request Exclusive Discount on this Report @ https://www.kdmarketresearch.com/discount/3138

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

 Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

 Contact us -

KD Market Research

150 State Street, Albany,

New York, USA 12207

Website: www.kdmarketresearch.com

Email id-  sales@kdmarketresearch.com

Read More :https://kdmarketresearch.blogspot.com/

https://automotiveindustrylatestreport.blogspot.com/

https://pharmaceuticalindustryupdate.blogspot.com/

[sapanas]

COVID 19 Impact Analysis: DPT vaccine Market Size, Share, Growth, Forecast, Key Findings And Competitive Landscape

Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on DPT vaccine Market and demographic challenges, showed how it could move forward in the coming years.

DPT vaccine Market Key Players

Some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others.

Diphtheria Tetanus and Pertussis (DPT) vaccine Market - Overview

Global Diphtheria Tetanus and Pertussis Vaccine (DPT) vaccine Market Size is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.

There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.

Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.

However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1357

DPT vaccine Market - Regional Analysis

Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.

The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.

Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.

Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.

The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.

Global DPT vaccine Market - Company Analysis

Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.

Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/dpt-vaccine-market-1357

Latest Industry News

The Indian Industries Association (IIA) has decided to help the UP government in India to implement the one district one product (ODOP) scheme in 45 districts where the industry lobby group has a direct presence. 23 JUL 2018

The Department of Health-Center for Health Development (DOH-CHD) has started a vaccination program in Western Visayas, Philippines. It is counting on the support of local government units (LGUs) for the success of this program. In this program, the basic vaccination includes one dose of the BCG vaccine, three doses of the DPT vaccine, one dose of the MMR vaccine, and three doses of polio vaccine. 11 DEC 2018

[dpimarketreports]

Newly Published DPIResearch Report-Human Vaccine Market Research Report

DPI Research published a new report on Global Human Vaccines Market. The research offers an extensive analysis of key players active in the Global Human Vaccines Market. Detailed analysis on operating business segments, product portfolio, business performance, and key strategic developments is offered in the research. Leading market players analyzed in the report include: Sanofi Pasteur, GlaxoSmithKline (GSK), Merck, Pfizer, AstraZeneca, Mitsubishi Tanabe Pharma, Emergent Biosolutions, etc.

Download Report Sample: https://dpiresearch.com/request-a-free-sample-report/

The global market size for human vaccines is anticipated to observe tremendous growth projections during 2019 – 2025.

The prominent factors that are expected to contribute to the growth of the global human vaccines market during the forecast period:

Increased Disease Awareness

Approval/launches of the New Vaccines

Rising focus on immunization programs

Increasing government support for the vaccine development

Highlighted with 35 tables and 140 figures, this 310-page report “Global Human Vaccines Market Size, Trends, Opportunities and Growth Potential” provides a comprehensive analysis of the fast-evolving, high-growth global human vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the global human vaccines market. The report provides historical market data for 2015 – 2018, and forecasts from 2019 till 2025.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025. The report provides in-depth analysis, information and revenue according to segments such as disease indications, end-users, leading vaccines, and companies from 2015 to 2018 and forecasts to 2025. A comprehensive analysis has been done on market share with percentage of all the segments.

Enquire for customization in Report @: https://dpiresearch.com/services/custom-research-services-providing-focused-comprehensive-tailored-research/

Key trends in terms of collaboration, partnerships, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2025.

The report concludes with the profiles of the key players in the global human vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, vaccines revenue analysis and recent development.

Other emerging players are making novel technology-based vaccines which are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology and diseases which are seeing vaccines development activity such as infectious diseases, non-infectious diseases, emerging pathogens, and recent development.

Key Topics Covered in the Report:

The Market Size of the Global Human Vaccines Market

The Market Size of the Global Pediatric Vaccines Market

The Market Size of the Global Adult Vaccines Market

The Market Size of the 42 Leading Vaccines

The Market Size of the Pneumococcal Disease, Diphtheria, Tetanus and Pertussis (DTP), Influenza, Human Papillomavirus (HPV), Meningococcal, Hepatitis, Measles, Mumps, and Rubella (MMR), Rotavirus, Varicella.

Thoroughly Evaluates Market Share of the Segments such as Disease Indications, End Users, Leading Vaccines, and Companies

Investigates the Key Growth Drivers and Restraints of the Global Human Vaccines Market

Provides Key Trends with Respect to Collaboration, Partnerships, Merger & Acquisition, Distribution, Exclusive and Licensing Agreement

A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development

An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Platform Technology, and Recent Development

For More Information@ https://dpiresearch.com/reports/global-human-vaccines-market/

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@dpiresearch.com

Customization of the Report:

DPI Research provides customization of the report as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

DPI Research is a leading market research publisher which offer bespoke market research reports, custom research and consulting services across multi geographies and industry verticals. We deliver a wide range of cutting-edge research solutions that help organizations in making better decisions of the business to business needs.

DPI Research provides a high standard of business research reports to the clients across industry verticals comprising Life Sciences, Information Technology, Telecom & Internet, Food Beverages & Agriculture, Travel & Tourism, Consumer Goods & Retail, Education and Social Sciences. We are committed to using advanced analytical tools and methodologies to help clients with crucial industry information for decision making.

DPI Research approaches for business research led by a team of dynamic industry experts. DPI Research provides real insight for effective decisions to help business with the help of current source and accurate data available in the market. DPI Research reaches across the globe with global standards from established markets in North America and Europe to emerging markets in South America, Asia-Pacific, Middle East, and Africa to provide the best business solutions.

Contact Us: Maria Rai Head of Business Development DPI Research | Web: https://dpiresearch.com Direct Line: +91-766-764-8693 E-mail: sales@dpiresearch.com

[ketan-wagh121-blog]

Covid-19 Impact on Human Vaccines Market Segmentation, Parameters and Prospects 2019 to 2025 Market Research Report

Global Human Vaccines Industry

Market Analysis

A vaccine, simply put, is a biological preparation that helps in improving the immunity of a specific disease. Typically it comprises of an agent that resembles a disease-causing microorganism which is made from killed or weakened forms of microbes or their toxins. Vaccines help in protecting humans against various life-threatening diseases as it helps in preparing their immune system for defending itself. Proper vaccination plays a key role in improving public health and keep humans healthy. Vaccinations are regarded as a cornerstone of present human preventative medicine. They have evolved over the years due to advancements in the healthcare center, thereby resulting in an increase in the capability of vaccination in keeping humans healthy and decreasing adverse reactions. Vaccinations protect people against serious diseases as well as prevent it from spreading to others.

Try Sample of Global Human Vaccines Market @ https://www.wiseguyreports.com/sample-request/4511784-global-human-vaccines-market-size-trends-opportunities-and-growth-potential

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Numerous factors are propelling the human vaccines market growth. These include growing support from the government for vaccine development, increasing focus on immunization programs, launches/approvals of new vaccines, increased disease awareness, fewer side effects, and growing awareness about the different benefits of taking vaccines.

On the flip side, strict regulatory rules, high cost, storage, transportation, and handling are factors that may deter the human vaccines market growth.

Market Segmentation

The report offers a thorough analysis of the human vaccines market segmentation based on end user, disease indication, and leading vaccines for a thorough understanding.

Based on disease indication, the human vaccines market is segmented into human papilloma virus (HPV), measles, mumps, and rubella (MMR), diphtheria, tetanus, and pertussis (DTP), pneumococcal disease, varicella, rotavirus, hepatitis, meningococcal, and influenza.

Based on the end user, the human vaccines market has been segmented into adult vaccines and pediatric vaccines.

Based on leading vaccines, the human vaccines market has been segmented into Imvamune, EasySix, Anflu, BiLive, HeaLive, In Live, Ixiaro, Dukoral, Bio Thrax, Flumist/Fluenz, Jebik V, Varicella (MTP), Mearubik, Tetrabik, Biken Ha, Ticovac, Pediarix, Infanrix, Synflorix, Rotarix, Zostavax, Rotateq, Pentacel, Pentaxim, Hexaxim, Imovax, Shingrix, Trumenba, Cervarix, Menveo, Bexsero, Boostrix, Adacel, M-M-R II, Priorix, Varilix, Priorix Tetra, Havrix/Engerix/Twinrix-B, Flaurix/FluLaval, Pneumovax 23, Proquad, Menactra, Varivax, Flublok, Fluzone, Vaxigrip, Gardasil/Gardasil 9, and Prevnar/Prevnar 13.

Regional Analysis

Geographically, the human vaccines market has been segmented into North America, the Middle East and Africa, the Asia Pacific, and Europe.

The human vaccines market in North America is predicted to have a healthy growth owing to the presence of improved healthcare facilities in this region.

Europe is predicted to possess a significant growth chiefly on account of increasing awareness about vaccines, especially in developing economies.

The human vaccines market in the APAC region is predicted to have notable growth owing to the manufacturing of new vaccines and the presence of key players.

The human vaccines market in the MEA is predicted to have stable growth.

Industry News

October 2019: Researchers at Icahn School of Medicine has joined hands with PATH, the University of Chicago, the Duke Early Phase Clinical Research Unit, and the Children’s Hospital Medical Center at Cincinnati to create a universal flu vaccine which will cover all influenza strains.

For Detailed Reading Please visit WiseGuy Reports @  https://www.wiseguyreports.com/reports/4511784-global-human-vaccines-market-size-trends-opportunities-and-growth-potential

For more information or any query mail at sales@wiseguyreports.com

About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[aditi-us]

Conjugate Vaccine Market Is Expected to expand at a CAGR of 14.6% Forecast period 2018-2023

A Comprehensive research study conducted by KD Market Insights on " Global Conjugate Vaccine Market (2018-2023) " report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Conjugate Vaccine Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments. Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. The global conjugate vaccine market is expected to grow at a CAGR of 14.6%, leading to a global revenue of USD 100.59 Bn by 2023. By volume, it is anticipated to reach 9600.56 Million units by 2023, expanding at a CAGR of 17.2%. The conjugate vaccine market is classified into two primary segments-based on disease indication: pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others; and based on end user: paediatric and adult. Asia-Pacific will have the highest CAGR during the forecasted period. Request for Sample @ https://www.kdmarketinsights.com/sample/3225 Key growth factors: - Rising adoption of cancer therapeutic vaccines, improvement in patient compliance along with an increasing product pipeline, and growing efforts for the adoption of appropriate preventive screening methods to help avert adverse reactions will accelerate the market. - Conjugate Vaccine market is expected to have positive growth owing to technological advancements, growth initiatives for the production of low-cost vaccines, and widespread routine vaccination programs in emerging economies. Threats and key players: - Although the conjugate vaccine market is expected to have a positive growth globally, lack of awareness, shortage risk, the situation of oligopoly, uncertainty about the future of international initiatives, emerging manufacturers, and costs and prices of new vaccines will hinder growth. - Major Conjugate Vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, Novartis, etc. Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/global-conjugate-vaccine-market Table of Contents: Chapter 1: Executive summary 1.1 Market scope and segmentation 1.2 Key questions answered in this study 1.3 Executive summary - I 1.4 Executive summary – II Chapter 2: Market overview 2.1. Market definitions 2.2. Global market overview – by revenue - Global historical (2015-2017) market revenue (USD Bn) - Global forecasted (2018-2023) market revenue (USD Bn) - Geography-wise market (2018-2023) revenue (USD Bn) 2.3. Global market overview – by volume - Global historical (2015-2017) market volume (Million units) - Global forecasted (2018-2023) market volume (Million units) - Geography-wise (2018-2023) market volume (Million units) 2.4. Global market drivers and challenges 2.4.1. Global market drivers 2.4.2. Global market challenges 2.5. Global market trends 2.6. Value chain 2.7.1. Regional market overview - North America - Observation - Key competitors 2.7.1(A) Regional market overview – North America by revenue and by volume - North America historical (2015-2017) market revenue (USD Bn) - North America forecasted (2018-2023) market revenue (USD Bn) - North America historical (2015-2017) market volume (Million units) - North America forecasted (2018-2023) market volume (Million units) 2.7.2. Regional market overview – Europe - Observation - Key competitors 2.7.2(A) Regional market overview – Europe by revenue and by volume - Europe historical (2015-2017) market revenue (USD Bn) - Europe forecasted (2018-2023) market revenue (USD Bn) - Europe historical (2015-2017) market volume (Million units) - Europe forecasted (2018-2023) market volume (Million units) 2.7.3. Regional market overview – Asia-Pacific - Observation - Key competitors 2.7.3(A) Regional market overview – Asia Pacific by revenue and by volume - Asia Pacific historical (2015-2017) market revenue (USD Bn) - Asia Pacific forecasted (2018-2023) market revenue (USD Bn) - Asia Pacific historical (2015-2017) market volume (Million units) - Asia Pacific forecasted (2018-2023) market volume (Million units) 2.7.4. Regional market overview – Latin America - Observation - Key competitors 2.7.4(A) Regional Market Overview – Latin America by revenue and by volume - Latin America historical (2015-2017) market revenue (USD Bn) - Latin America forecasted (2018-2023) market revenue (USD Bn) - Latin America historical (2015-2017) market volume (Million units) - Latin America forecasted (2018-2023) market volume (Million units) 2.7.5. Regional market overview – Middle East & Africa - Observation - Key competitors 2.7.5(A) Regional market overview – Middle East & Africa by revenue and by volume - Middle East & Africa historical (2015-2017) market revenue (USD Bn) - Middle East & Africa forecasted (2018-2023) market revenue (USD Bn) - Middle East & Africa historical (2015-2017) market volume (Million units) - Middle East & Africa forecasted (2018-2023) market volume (Million units) Chapter 3: Major segment overview - global by disease indication 3.1. Disease indication: Pneumococcal, Hib - by revenue, by volume, CAGR - Overview - by disease indication - Market share (2015, 2018 & 2023): Pneumococcal – global revenue (USD Bn) - Market share (2015, 2018 & 2023): Pneumococcal – global volume (Million units) - Market share (2015, 2018 & 2023): Hib – global revenue (USD Bn) - Market share (2015, 2018 & 2023): Hib – global volume (Million units) 3.2. Disease indication: DTP, Meningococcal - by revenue, by volume, CAGR - Overview - by disease indication - Market share (2015, 2018 & 2023): DTP – global revenue (USD Bn) - Market share (2015, 2018 & 2023): DTP – global volume (Million units) - Market share (2015, 2018 & 2023): Meningococcal – global revenue (USD Bn) - Market share (2015, 2018 & 2023): Meningococcal – global volume (Million units) Continue… Check for Discount @ https://www.kdmarketinsights.com/discount/3225 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: sales@kdmarketinsights.com Website: www.kdmarketinsights.com

[ashukalbande21-blog]

Human Vaccines Market to Perceive an Aggrandizing Growth by 2022: Prognosticates MRFR

MRFR is the Leading Brand in The Research Company who Recently Published Human Vaccines Market Research Reports which includes Study of growth, Regional Analysis, Top Industry Players Formation, Major Drivers, Upcoming Trends and Forecast to 2022.

Market Scenario: A vaccine is a biological preparation which contains a weakened or killed microbial agent, its toxins or its surface proteins, which provides active acquired immunity against the disease caused by the microbe. The aim of vaccination is to stimulate and train the body immunity to recognize and destroy the microbial threat in later encounters. Vaccination is the most effective method of preventing infectious diseases and is largely responsible for eradicating many deadly diseases such as smallpox and the restriction of diseases such as measles, and tetanus.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2671

Middle East and Africa are laggards when it comes to immunization coverage. According to World Health Organization (WHO), out of the total number of children worldwide who did not receive the required three doses of diphtheria-tetanus-pertussis vaccines, more than 40% were from sub-Saharan Africa. Other nations with large unvaccinated population include Nigeria, Iraq, Chad, Niger, Angola, Somalia and Sudan. UNICEF estimates that in 2015, Central African Republic, Equatorial Guinea, Somalia, South Sudan, Syrian Arab Republic and Ukraine had less than 50%coverage of the third dose of diphtheria, tetanus and pertussis (DTP) vaccine. More than half of the unvaccinated children live in Democratic Republic of Congo, Ethiopia, India, Indonesia, Iraq, Nigeria, Pakistan, Philippines, Uganda and South Africa. Thus Middle East and Africa offer immense potential and opportunities for the vaccine market. Apart from the unmet needs for vaccination, second most important market driving factor are the policies of national Governments and international bodies such as World health organization (WHO). For example vaccine action plan of WHO along with huge funding from international bodies were responsible for driving the vaccine market to great heights in the past and also resulted in development and expansion of vaccine production capacities especially in developing states notably India. Other driving factors are increasing funds from philanthropy organizations such as Bill and Melinda Gates foundation, inclusion of several new vaccines in the national immunization schedule of many countries, development of new vaccines which includes vaccine for hepatitis, growing awareness of vaccination, growth of manufacturing low cost vaccines especially in developing countries, the entry of China in the vaccine market etc. The market’s constraints include falling profitability of vaccine, manufacturing, eradication of diseases such as smallpox which effectively eliminates the need for vaccine, side effects associated with vaccines, variability of efficacy of vaccines and difficulty of producing vaccines for microbes with high mutations such as HIV. The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.

The market’s trends include strong research pipeline under which number of novel vaccines are being developed such as rubella vaccine, ebola vaccine etc. DNA recombinant technology is also a common technology used in the development of novel acting vaccines. Taking all the factors into consideration, we expect the Middle East and Africa human vaccines market which was $ 2.8 billion in 2015 to reach around $ 5.46 billion in future, growing at a CAGR of 11.8%.

Key Players for Middle East and Africa Human Vaccines Market: Some of the key players in this market are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.

Segments:

Middle East and Africa human vaccines market has been segmented on the basis of technology which comprises attenuated, inactivated, toxoid, conjugate & subunit, recombinant DNA. On the basis of disease indication; market is segmented into pneumococcal, influenza, hepatitis, rotavirus, DTP, polio and others. On the basis of type the market is segmented into prophylactic and therapeutic. On the basis of composition market is again segmented into mono vaccine and combination vaccines. The route of administration segments the market into oral, injectable and other. Moreover on the basis of end user; market is segmented into children and adults.

Regional Analysis of Middle East and Africa Human Vaccines Market:

Depending on geographic region, human vaccine market is segmented into several countries: UAE is the largest market for human vaccines in the entire Middle East and Africa human vaccines market closely followed by Egypt. The rest of Africa’s market especially Sub Saharan regions are however the fastest growing market with a huge unmet medical needs.

Browse Full Reports @ https://www.marketresearchfuture.com/reports/human-vaccines-market-2671

[paullassiterca]

Top Tips to Avoid Pharmaceutical Injury

30 Tips in 30 Days Designed to Help You Take Control of Your Health

This article is included in Dr. Mercola’s All-Time Top 30 Health Tips series. Every day during the month of January, a new tip will be added that will help you take control of your health. Want to see the full list? Click here.

Vaccines have quickly become Big Pharma’s most lucrative profit center. Currently valued at more than $34 billion a year, the vaccine industry is projected to exceed $49 billion by 2022.1 There are several reasons for this rapid growth. Not only are vaccines priced much higher than pills, but governments and nongovernmental organizations (NGOs) are also engaged in the marketing of vaccines.

These unethical partnerships, which use both taxpayer and NGO money, advance misleading research intended to frighten the public. Worse, they discredit vaccine critics who raise legitimate safety and efficacy questions and even discredit the families and victims of vaccine injuries themselves.

To cash in on vaccine profits, Big Pharma, governments and NGOs have cast all vaccines as “life-saving.” One of the clearest examples is the attempt to present the HPV vaccine as an “anticancer” vaccine, even though there’s not a single shred of evidence that it actually has an impact on cervical cancer rates. Meanwhile, mounting evidence of serious harm and death caused by the HPV vaccine is being ignored or cast aside as “coincidental.”

To Avoid Vaccine Injury, Educate Yourself About the Risks

The official stance repeated by most mainstream media is that vaccines have been thoroughly researched, that “hundreds” of studies have proven their safety, and that no link between vaccines and health problems, such as autism, have ever been found.

It sounds definitive enough, and is often repeated as established fact. Yet it’s far from the whole truth. Importantly, the vaccine industry has long shied away from evaluating vaccinated versus unvaccinated populations to determine potential differences in general health outcomes.

The few independent scientists who have attempted such an investigation have little comfort to give to those who believe vaccines are essential for health, and mandatory use of vaccines by all children is the only way to protect society from disease.

Vaccine May Actually Be Doing More Harm Than Good

One such study,2 published in 2017, examined health outcomes among infants 3 to 5 months old following the introduction of diphtheria-tetanus-pertussis (DTP) and oral polio vaccine in Guinea-Bissau, which took place in the early 1980s. This population offered the rare opportunity to compare vaccinated and unvaccinated children due to the way the vaccines were rolled out in the West African country.

Shockingly, researchers discovered “DTP was associated with fivefold higher mortality than being unvaccinated.” According to the authors, “All currently available evidence suggests that DTP vaccine may kill more children from other causes than it saves from diphtheria, tetanus or pertussis.”

In short, the researchers concluded that DTP vaccine weakened the children’s immune systems, rendering them vulnerable to a whole host of other often deadly diseases and serious health problems.

In the U.S., the Centers for Disease Control and Prevention (CDC) now recommends that children receive 69 doses of 16 vaccines by the time they’re 18 years old, with 50 doses of 14 vaccines given before the age of 6.3

This, despite the fact that no thorough investigation has ever been conducted to determine how all of these vaccines actually affect a child’s health. What’s worse, no one is tracking the health outcomes of children who adhere to the federally recommended childhood vaccine schedule and state mandatory vaccination programs.

Lawyers with the U.S. Justice Department also defend vaccines in the federal vaccine injury compensation program (VICP), commonly referred to as “vaccine court,” which means the U.S. government has a stake in maintaining the illusion that vaccines are a necessary lifesaving measure that causes minimal harm.

High Vaccination Rate Does Not Translate Into Better Infant Health

What we do know is that:

• The U.S. has the highest vaccination rate in the world, with 94 to 96 percent of children entering kindergarten having received multiple doses of vaccines4

• The U.S. also has one of the highest infant and maternal mortality rates of any developed nation5,6

• 1 in 6 American children has a developmental disability, which includes ADD, ADHD, autism, hearing loss, learning disabilities, mental disabilities, seizures and stammering — many of which are also listed or known side effects of vaccines

• 54 percent of children have a diagnosed chronic illness, including anxiety, asthma, behavioral problems, bone and muscle disorders, chronic ear infections, depression, diabetes, food and/or environmental allergies and epilepsy.

This list again mirrors many of the acknowledged side effects of vaccines, and the rise in prevalence of these diseases parallel the rise in required vaccines, yet vaccine promoters insist that these illnesses are in no way associated with vaccinations

Common Vaccine Side Effects

Both the U.S. Congress and the Supreme Court have also admitted that government licensed and recommended childhood vaccines are “unavoidably unsafe,”7 and possible side effects that are actually listed on vaccine inserts include:

Autoimmune diseases

Food allergies

Asthma

Eczema

Type 1 diabetes

Rheumatoid arthritis

Tics

Tourette syndrome

ADD/ADHD

Autism

Speech delay

Neurodevelopment disorders

Sudden infant death syndrome (SIDS)

Seizure disorder

Narcolepsy

Vaccines also have the highest number of recalls of any drug, which speaks to their “unavoidably unsafe” nature. Victims have also received compensation from the federal vaccine injury compensation program (VICP) for the following (and other) injuries:

Guillain-Barre syndrome

Transverse myelitis

Encephalopathy

Seizure disorder hypoxic seizure

Death

Brachial neuritis

Acute disseminated encephalomyelitis

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Premature ovarian failure

Bell’s palsy

Type 1 diabetes

Idiopathic thrombocytopenic purpura

Rheumatic arthritis

Multiple sclerosis

Fibromyalgia

Anaphylaxis

Ocular myasthenia gravis

Infantile spasms

The Vaccines-Autism Link Revived

According to the latest survey,8,9 1 in 40 American children between the ages of 3 and 17 is now on the autism spectrum. This shocking update was published in the journal Pediatrics in December 2018. In 2014, the rate was 1 in 59; in 2010, it was 1 in 68; in 2000, it was 1 in 150.10 To say we’re looking at exponential growth would be an understatement. But do vaccines have anything to do with this trend?

According to a Full Measure report11 by award-winning investigative reporter and former CBS correspondent Sharyl Attkisson, Dr. Andrew Zimmerman, a pediatric neurologist, was the pro-vaccine expert witness the government used to debunk and turn down autism claims in vaccine court.

“Zimmerman was the government’s top expert witness and had testified that vaccines didn’t cause autism. The debate was declared over,” Attkisson reports. “But now Dr. Zimmerman has provided remarkable new information.

He claims that during the vaccine hearings all those years ago, he privately told government lawyers that vaccines can, and did cause autism in some children. That turnabout from the government’s own chief medical expert stood to change everything about the vaccine-autism debate. If the public were to find out …

And he has come forward and explained how he told the United States government vaccines can cause autism in a certain subset of children and [the] United States government, the Department of Justice [DOJ], suppressed his true opinions.”

Robert F. Kennedy Jr., chairman of The World Mercury Project, was the one who convinced Zimmerman to speak out about the cover-up. In a sworn affidavit, dated September 7, 2018, Zimmerman states that, in 2007, he told DOJ lawyers he had “discovered exceptions in which vaccinations could cause autism.”

“I explained that in a subset of children … vaccine-induced fever and immune stimulation … did cause regressive [brain disease] with features of autism spectrum disorder,” Zimmerman writes.

A week after this 2007 meeting, the DOJ fired him, saying his services would no longer be needed. According to Zimmerman, the DOJ then went on to misrepresent his opinion in future cases, making no mention of the exceptions he’d informed them of. Kennedy has now filed a fraud complaint with the DOJ Inspector General.

William Thompson, Ph.D., a senior scientist at the CDC’s National Center for Immunizations and Respiratory Diseases, has also confessed to covering up links found between vaccines and autism, in this case the measles-mumps-rubella (MMR) vaccine.

According to Thompson, this scientific fraud was committed for the express purpose of covering up potential safety problems so the agency would be able to maintain that the MMR vaccine had been proven safe to give to all children. By eliminating the incriminating data, the link vanished, and this research has been cited as proof ever since that vaccines don’t cause autism.

Attkisson���s report also reveals how Congressmen who wanted to investigate the autism-vaccine link were bullied, harassed and threatened. Dan Burton (R-IN), Dr. Dave Weldon (R-FL) and Bill Posey (R-FL) are among 11 current and former members of Congress and staff who told Attkisson they were warned to drop the vaccine safety issue by PhRMA lobbyists.

Vaccines Can Have Serious Consequences for Adults Too

While children are more susceptible to vaccine damage than adults, grownups can and have been seriously injured and killed by routine vaccinations as well. It’s important to realize that no vaccine is 100 percent safe for everyone. As reported by CNN, an oncologist with London’s Royal Marsden NHS Foundation Trust recently died following a routine yellow fever vaccination:12

“Martin Gore, 67, died Thursday morning after receiving the vaccine, which is recommended to travelers visiting sub-Saharan Africa, most of South America, and parts of Central American and the Caribbean …

Gore’s death casts light on the heightened risk associated with the yellow fever vaccine and the over-60 demographic. Typical side effects of the vaccine include headaches, muscle pain, mild fever and soreness at the injection site …

However, the vaccinations can, in rare circumstances, cause more severe side effects, including allergic reactions and problems affecting the brain or organs …

The WHO reported that all cases of viscerotropic disease — a rare but dangerous side effect of yellow fever vaccinations where an illness similar to wild-type yellow fever proliferates in multiple organs — have occurred in primary vaccines, starting two to five days after vaccination.”

Might Vaccine Reaction Rate Be as High as 1 in 10?

In the video above, Del Bigtree,13 an Emmy Award-winning producer of “The Doctors” talk show for six years, and one of the producers of the documentary, “Vaxxed,” discusses vaccine safety, or rather the lack thereof.

In it, he recounts how, in 2010, the CDC hired a company to automate the federal vaccine adverse event reporting system (VAERS) in such a way that any potential vaccine reactions reported to doctors participating in the Harvard Pilgrim HMO would automatically be uploaded into the VAERS database.

Remarkably, preliminary data showed that out of 376,452 individuals given 45 different vaccines, 35,570 possible vaccine reactions were identified. This means nearly 1 in 10 people suffered a reaction after vaccination concerning enough to be reported, yet the official CDC mantra is that the risk for serious vaccine injury or death is 1 in 1 million.

Unfortunately, while the creation of VAERS in 1986 was an opportunity to get a firmer grasp of the number of potential vaccine reactions, injuries and deaths occurring after vaccinations given in the U.S., the CDC didn’t follow through, and the project fell by the wayside.

Medical Errors Are the Third Leading Cause of Death in the US

While I’ve focused a lot of attention on vaccines and the necessity for educating yourself about their risks in this article, vaccines are by far not the only hazard presented by the medical industry. In fact, medical errors in general are the third leading cause of death, killing an estimated 250,000 Americans each year,14,15 an increase of about 25,000 people annually from data published in 2000.16

Side effects from drugs, taken as prescribed, account for the vast majority of iatrogenic deaths, but unnecessary surgeries, medication errors in hospitals, hospital-acquired infections and other medical errors occurring in hospitals also claim their fair share of lives.

Research17 published in 2013 estimated that preventable hospital errors kill 210,000 Americans each year — a figure that comes very close to the latest statistics. However, when deaths related to diagnostic errors, errors of omission, and failure to follow guidelines were included, the number skyrocketed to 440,000 preventable hospital deaths each year.

10 Tips to Avoid Medical Harm

How can you avoid becoming one of these statistics? Aside from educating yourself on the risks and benefits of vaccines, here are several additional suggestions:

Ask your doctor whether a recommended test and/or treatment is really necessary, and do your own homework — According to a report by the Institute of Medicine, an estimated 30 percent of all medical procedures, tests and medications may be unnecessary,18 any one of which can put you at risk for a potentially serious or lethal side effect.

An investigation19 by the Mayo Clinic published in 2013 also revealed between 40 and 78 percent of the medical testing, treatments and procedures you receive are of no benefit to you — or are actually harmful — as determined by clinical studies. To learn which tests and interventions may do more harm than good, browse through the Choosing Wisely website.20

Avoid hospitals unless absolutely necessary — According to 2011 statistics, 1 in 25 patients in the U.S. end up contracting some form of infection while in the hospital,21 and 205 Americans die from hospital-acquired infections each and every day.22

Do your due diligence before undergoing endoscopy — If you’re having a colonoscopy or any other procedure using a flexible endoscope done, you can significantly reduce your risk of contracting an infection by asking the hospital or facility how the scope is cleaned, and which cleaning agent is used.

Some esophagoscopes and bronchoscopes have sterile sheaths with disposable air-water and biopsy channels, but many others do not, and must be cleaned between each use. If the hospital or clinic uses glutaraldehyde, or the brand name Cidex, cancel your appointment and go elsewhere.

About 80 percent of clinics use glutaraldehyde because it’s a less expensive alternative; however, it does not do a good job of sterilizing the equipment. If they use peracetic acid, your likelihood of contracting an infection from a previous patient is slim.

To learn more about this, see my interview with David Lewis, Ph.D., in “How Improper Sterilization of Endoscopes Could Put Your Health at Risk.”

Enlist a health care advocate — Once hospitalized, you’re at risk for medical errors, so one of the best safeguards is to have someone there have someone there with you. It’s important to have a personal advocate present to ask questions and take notes.

For every medication given in the hospital, ask questions such as: “What is this medication? What is it for? What’s the dose?” Most people, doctors and nurses included, are more apt to go through that extra step of due diligence to make sure they’re getting it right if they know they’ll be questioned about it.

To learn more, listen to my interview with Dr. Andrew Saul in “What Hospitals Won’t Tell You — Vital Strategies That Could Save Your Life,” or pick up a copy of his book, “Hospitals and Health: Your Orthomolecular Guide to a Shorter Hospital Stay.”

In it, he discusses the dangers of hospital stays, the type of patient that tends to get killed most frequently, and how you can protect your health and life in the event you have to be hospitalized. For example, reminding nurses and doctors to wash their hands and change gloves before touching you can go a long way toward avoiding contamination with potentially lethal microbes.

Do your own prep for surgery — If you or someone you know is scheduled for surgery, print out the WHO surgical safety checklist and implementation manual,23 which is part of the campaign “Safe Surgery Saves Lives.” The checklist can be downloaded free of charge here. Print it out and bring it with you, as this can help you protect yourself, your family member or friend from preventable errors in care.

Know the most effective protocol for sepsis — Sepsis is a progressive disease process initiated by an aggressive, dysfunctional immune response to an infection in the bloodstream, which is why it’s sometimes referred to as blood poisoning. Each year, an estimated 1 million Americans get sepsis24,25 and up to half of them die as a result.26,27,28

Symptoms of sepsis are often overlooked, even by health professionals, and without prompt treatment, the condition can be deadly.

Unfortunately, conventional treatments often fail, and most hospitals have yet to embrace the use of intravenous (IV) vitamin C, hydrocortisone and thiamine,29 a treatment developed by Dr. Paul Marik, which has been shown to reduce sepsis mortality from 40 to a mere 8.5 percent.30,31 Common signs and symptoms of sepsis to watch out for include:32

A high fever

Inability to keep fluids down

Rapid heartbeat; rapid, shallow breathing and/or shortness of breath

Lethargy and/or confusion

Slurred speech, often resembling intoxication

Should a few or all of these be present, seek immediate medical attention to rule out sepsis. Also inform the medical staff that you suspect sepsis, as time is of the essence when it comes to treatment, and urge them to use Marik’s protocol (currently the standard of care for sepsis at Sentara Norfolk General Hospital, where Marik works). You can learn more about this protocol by following the hyperlink provided above.

Optimize your vitamin D instead of getting the flu vaccine — Research33,34 shows vitamin D optimization is a more effective flu prevention strategy than flu vaccination, reducing respiratory infections such as influenza by 50 percent in those with vitamin D blood levels below 10 ng/mL. People with higher vitamin D levels at baseline may reduce their risk by about 10 percent, which the researchers stated was about equal to the effect of flu vaccines.

Aside from vitamin D, loading up on vitamins B1 and C may go a long way toward keeping you healthy through the flu season and beyond. Influenza has also been successfully treated with high-dose vitamin C.35 Taking zinc lozenges at the first sign of a cold or flu can also be helpful.

Avoid antibiotics — Drugs are vastly overprescribed and misused, and this is particularly true for antibiotics. Avoid using them unless absolutely necessary, and remember they don’t work for viral infections. Unnecessary use of antibiotics is one of the driving causes of antibiotic-resistant superbugs.

Turn a deaf ear to drug ads — While drug makers are required to inform consumers about potential side effects in their ads, they’ve perfected drug ad narration to make them less frightful.36

Avoid drugs, unless absolutely necessary — As mentioned, drugs — taken as prescribed — account for a majority of the 250,000 people who die from medical mistakes in the U.S. each year. A great many, if not most, diseases can be effectively addressed using simple lifestyle changes.

Key factors include diet, exercise and nonexercise movement, sleep and stress reduction. To investigate your options, you can search my database of tens of thousands of articles simply by entering your condition in the search engine.

Among the most lethal drugs right now are the opioids, which need to be used with extreme care and only in the short term. For treatment options, see “Treating Pain Without Drugs,” and “Study Reveals Previously Unknown Mechanism Behind Acupuncture’s Ability to Reduce Pain,” which also provides a long list of other drug-free pain relief strategies.

Tip #21Make Magnesium a Priority

from Articles http://articles.mercola.com/sites/articles/archive/2019/01/22/tips-to-avoid-medical-harm.aspx source https://niapurenaturecom.tumblr.com/post/182210854766

[kdmarketresearch]

New product development and trends of Conjugate Vaccines Market (2019 - 2022)

A Comprehensive research study conducted by KD Market Research on Conjugate Vaccines Market Opportunity Analysis and Industry forecast. report offers extensive and highly detailed historical, current and future market trends in Conjugate Vaccines Market. Conjugate Vaccines Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.

Request for sample@  https://www.kdmarketresearch.com/sample/3138

The market for conjugate vaccines is expected to increase, owing to global awareness about the benefits of vaccination for the prevention of certain life-threatening diseases, growing initiatives for production of low-cost vaccines, and widespread routine vaccination programmes in emerging economies. The market will witness a steady growth, expanding at a compound annual growth rate (CAGR) of 11.7% during 2017-2022, to reach approximately USD 87.7 Bn by 2022.

Disease indication segment insights:

Pneumococcal conjugate vaccine (PCV) held the largest market share (24.66%) in 2017 owing to the widespread nature of pneumococcal disease. Also, the leading vaccine-preventable cause of death among children around the world is the pneumococcal disease. Global initiatives were undertaken to speed up the introduction of pneumococcal vaccinations in low-income countries through partnerships among countries, donors, academia, international organizations, and industries. Close on its heels, the diphtheria and tetanus toxoids and pertussis (DTP) conjugate vaccine occupied a share of 23% in 2017. The higher prevalence of respiratory diseases such as whooping cough, among both children and adults, have led to the increased adoption of DTP conjugate vaccines. Haemophilus influenzae type b (Hib) conjugate vaccines are expected to grow at the fastest rate during 2017–2022.

End user segment insights:

The adult segment registered higher market share than the paediatric segment because of an increase in awareness on conjugate vaccines for adults, over the years. Still, the penetration level for adult conjugate vaccines is comparatively lower, with the lowest being for PCVs. Hence, the growth potential is very high. The paediatric vaccines, on the other hand is a stable market and depends highly on the birth rates in each region. The vaccination programmes, especially taken up by global organizations such as the United Nations Educational, Scientific and Cultural Organization (UNESCO), have been successful in eradicating many such vaccine-preventable diseases.

Regional insights:

Asia-Pacific is the largest market for conjugate vaccines, which held a share of 42%, in 2017. The primary indicators of the potential for the vaccine market is the geriatric population in the region, especially in countries such as India and China. In turn, this has, encouraged market participants to increase spending on research and development (R&D) and distribution facilities in the these countries. North America is the second biggest market for conjugate vaccines, owing to the region’s widespread immunization programmes. The Middle East and Africa, and Latin America regions lack proper infrastructure and awareness of vaccine-preventable diseases, which are hindering market growth.

Companies covered: 1. GlaxoSmithKline 2. Pfizer Inc. 3. Merck & Co. 4. Novartis 5. Sanofi Pasteur 6. CSL Limited 7. Bharat Biotech International 8. Biological E Limited 9. Serum Institute of India

Browse full report with toc@ https://www.kdmarketresearch.com/report/3138/global-conjugate-vaccines-market-2019-2022

Table of content

Chapter 1. Executive summary

1.1. Market scope and segmentation 1.2. Key questions answered 1.3. Executive summary

Chapter 2. Global conjugate vaccine market – overview

2.1. Market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), geography-wise market revenue (USD Bn), and market attractiveness analysis 2.2. Market drivers 2.3. Market trends 2.4. Market challenges 2.5. Value chain analysis 2.6. Porter's five forces analysis 2.7. Segmentation based on disease indication (pneumococcal conugate vaccine (PCV), haemophilus influenzae type B (Hib) conjugate vaccine, diptheria, tetanus toxoids and pertussis (DTP) conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 2.8. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 3. North America conjugate vaccine market

3.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 3.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 4. Europe conjugate vaccine market

4.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 4.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 5. Asia-Pacific conjugate vaccine market

5.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 5.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 6. Latin America conjugate vaccine market

6.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 6.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 7. The Middle East and Africa conjugate vaccine market

7.1. Regional market overview - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.2. Segmentation based on disease indication (pneumococcal conugate vaccine [PCV], haemophilus influenzae type B [Hib] conjugate vaccine, diptheria and tetanus toxoids and pertussis [DTP] conjugate vaccine, meningococcal conjugate vaccine, and others) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations 7.3. Segmentation based on end user (pediatric vaccine, and adult vaccine) - historical (2014-2016) and forecasted (2017-2022) market size (USD Bn), and key market observations

Chapter 8. Competitive landscape

8.1. GlaxoSmithKline 8.1.a. Company snapshot 8.1.b. Products/services 8.1.c. Major initiatives/highlights 8.1.d. Growth strategy 8.1.e. Geographical presence 8.1.f. Key numbers Note: Similar information areas will be covered for the remaining competitors: 8.2. Pfizer Inc. 8.3. Merck & Co. 8.4. Novartis 8.5. Sanofi Pasteur 8.6. CSL Limited 8.7. Bharat Biotech International 8.8. Biological E Limited 8.9. Serum Institute of India

Chapter 9. Conclusion 9.1. Future outlook

Appendix 1. List of tables 2. Research methodology 3. Assumptions

Check for discount @  https://www.kdmarketresearch.com/discount/3138

About Us:

 KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

 Contact us - KD Market Research

150 State Street, Albany,

New York, USA 12207

Email id  sales@kdmarketresearch.com

[jerrytackettca]

Top Tips to Avoid Pharmaceutical Injury

30 Tips in 30 Days Designed to Help You Take Control of Your Health

This article is included in Dr. Mercola's All-Time Top 30 Health Tips series. Every day during the month of January, a new tip will be added that will help you take control of your health. Want to see the full list? Click here.

Vaccines have quickly become Big Pharma's most lucrative profit center. Currently valued at more than $34 billion a year, the vaccine industry is projected to exceed $49 billion by 2022.1 There are several reasons for this rapid growth. Not only are vaccines priced much higher than pills, but governments and nongovernmental organizations (NGOs) are also engaged in the marketing of vaccines.

These unethical partnerships, which use both taxpayer and NGO money, advance misleading research intended to frighten the public. Worse, they discredit vaccine critics who raise legitimate safety and efficacy questions and even discredit the families and victims of vaccine injuries themselves.

To cash in on vaccine profits, Big Pharma, governments and NGOs have cast all vaccines as "life-saving." One of the clearest examples is the attempt to present the HPV vaccine as an "anticancer" vaccine, even though there's not a single shred of evidence that it actually has an impact on cervical cancer rates. Meanwhile, mounting evidence of serious harm and death caused by the HPV vaccine is being ignored or cast aside as "coincidental."

To Avoid Vaccine Injury, Educate Yourself About the Risks

The official stance repeated by most mainstream media is that vaccines have been thoroughly researched, that "hundreds" of studies have proven their safety, and that no link between vaccines and health problems, such as autism, have ever been found.

It sounds definitive enough, and is often repeated as established fact. Yet it's far from the whole truth. Importantly, the vaccine industry has long shied away from evaluating vaccinated versus unvaccinated populations to determine potential differences in general health outcomes.

The few independent scientists who have attempted such an investigation have little comfort to give to those who believe vaccines are essential for health, and mandatory use of vaccines by all children is the only way to protect society from disease.

Vaccine May Actually Be Doing More Harm Than Good

One such study,2 published in 2017, examined health outcomes among infants 3 to 5 months old following the introduction of diphtheria-tetanus-pertussis (DTP) and oral polio vaccine in Guinea-Bissau, which took place in the early 1980s. This population offered the rare opportunity to compare vaccinated and unvaccinated children due to the way the vaccines were rolled out in the West African country.

Shockingly, researchers discovered "DTP was associated with fivefold higher mortality than being unvaccinated." According to the authors, "All currently available evidence suggests that DTP vaccine may kill more children from other causes than it saves from diphtheria, tetanus or pertussis."

In short, the researchers concluded that DTP vaccine weakened the children's immune systems, rendering them vulnerable to a whole host of other often deadly diseases and serious health problems.

In the U.S., the Centers for Disease Control and Prevention (CDC) now recommends that children receive 69 doses of 16 vaccines by the time they're 18 years old, with 50 doses of 14 vaccines given before the age of 6.3

This, despite the fact that no thorough investigation has ever been conducted to determine how all of these vaccines actually affect a child's health. What's worse, no one is tracking the health outcomes of children who adhere to the federally recommended childhood vaccine schedule and state mandatory vaccination programs.

Lawyers with the U.S. Justice Department also defend vaccines in the federal vaccine injury compensation program (VICP), commonly referred to as "vaccine court," which means the U.S. government has a stake in maintaining the illusion that vaccines are a necessary lifesaving measure that causes minimal harm.

High Vaccination Rate Does Not Translate Into Better Infant Health

What we do know is that:

• The U.S. has the highest vaccination rate in the world, with 94 to 96 percent of children entering kindergarten having received multiple doses of vaccines4

• The U.S. also has one of the highest infant and maternal mortality rates of any developed nation5,6

• 1 in 6 American children has a developmental disability, which includes ADD, ADHD, autism, hearing loss, learning disabilities, mental disabilities, seizures and stammering — many of which are also listed or known side effects of vaccines

• 54 percent of children have a diagnosed chronic illness, including anxiety, asthma, behavioral problems, bone and muscle disorders, chronic ear infections, depression, diabetes, food and/or environmental allergies and epilepsy.

This list again mirrors many of the acknowledged side effects of vaccines, and the rise in prevalence of these diseases parallel the rise in required vaccines, yet vaccine promoters insist that these illnesses are in no way associated with vaccinations

Common Vaccine Side Effects

Both the U.S. Congress and the Supreme Court have also admitted that government licensed and recommended childhood vaccines are "unavoidably unsafe,"7 and possible side effects that are actually listed on vaccine inserts include:

Autoimmune diseases

Food allergies

Asthma

Eczema

Type 1 diabetes

Rheumatoid arthritis

Tics

Tourette syndrome

ADD/ADHD

Autism

Speech delay

Neurodevelopment disorders

Sudden infant death syndrome (SIDS)

Seizure disorder

Narcolepsy

Vaccines also have the highest number of recalls of any drug, which speaks to their "unavoidably unsafe" nature. Victims have also received compensation from the federal vaccine injury compensation program (VICP) for the following (and other) injuries:

Guillain-Barre syndrome

Transverse myelitis

Encephalopathy

Seizure disorder hypoxic seizure

Death

Brachial neuritis

Acute disseminated encephalomyelitis

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Premature ovarian failure

Bell's palsy

Type 1 diabetes

Idiopathic thrombocytopenic purpura

Rheumatic arthritis

Multiple sclerosis

Fibromyalgia

Anaphylaxis

Ocular myasthenia gravis

Infantile spasms

The Vaccines-Autism Link Revived

According to the latest survey,8,9 1 in 40 American children between the ages of 3 and 17 is now on the autism spectrum. This shocking update was published in the journal Pediatrics in December 2018. In 2014, the rate was 1 in 59; in 2010, it was 1 in 68; in 2000, it was 1 in 150.10 To say we're looking at exponential growth would be an understatement. But do vaccines have anything to do with this trend?

According to a Full Measure report11 by award-winning investigative reporter and former CBS correspondent Sharyl Attkisson, Dr. Andrew Zimmerman, a pediatric neurologist, was the pro-vaccine expert witness the government used to debunk and turn down autism claims in vaccine court.

"Zimmerman was the government's top expert witness and had testified that vaccines didn't cause autism. The debate was declared over," Attkisson reports. "But now Dr. Zimmerman has provided remarkable new information.

He claims that during the vaccine hearings all those years ago, he privately told government lawyers that vaccines can, and did cause autism in some children. That turnabout from the government's own chief medical expert stood to change everything about the vaccine-autism debate. If the public were to find out …

And he has come forward and explained how he told the United States government vaccines can cause autism in a certain subset of children and [the] United States government, the Department of Justice [DOJ], suppressed his true opinions."

Robert F. Kennedy Jr., chairman of The World Mercury Project, was the one who convinced Zimmerman to speak out about the cover-up. In a sworn affidavit, dated September 7, 2018, Zimmerman states that, in 2007, he told DOJ lawyers he had "discovered exceptions in which vaccinations could cause autism."

"I explained that in a subset of children … vaccine-induced fever and immune stimulation … did cause regressive [brain disease] with features of autism spectrum disorder," Zimmerman writes.

A week after this 2007 meeting, the DOJ fired him, saying his services would no longer be needed. According to Zimmerman, the DOJ then went on to misrepresent his opinion in future cases, making no mention of the exceptions he'd informed them of. Kennedy has now filed a fraud complaint with the DOJ Inspector General.

William Thompson, Ph.D., a senior scientist at the CDC's National Center for Immunizations and Respiratory Diseases, has also confessed to covering up links found between vaccines and autism, in this case the measles-mumps-rubella (MMR) vaccine.

According to Thompson, this scientific fraud was committed for the express purpose of covering up potential safety problems so the agency would be able to maintain that the MMR vaccine had been proven safe to give to all children. By eliminating the incriminating data, the link vanished, and this research has been cited as proof ever since that vaccines don't cause autism.

Attkisson's report also reveals how Congressmen who wanted to investigate the autism-vaccine link were bullied, harassed and threatened. Dan Burton (R-IN), Dr. Dave Weldon (R-FL) and Bill Posey (R-FL) are among 11 current and former members of Congress and staff who told Attkisson they were warned to drop the vaccine safety issue by PhRMA lobbyists.

Vaccines Can Have Serious Consequences for Adults Too

While children are more susceptible to vaccine damage than adults, grownups can and have been seriously injured and killed by routine vaccinations as well. It's important to realize that no vaccine is 100 percent safe for everyone. As reported by CNN, an oncologist with London's Royal Marsden NHS Foundation Trust recently died following a routine yellow fever vaccination:12

"Martin Gore, 67, died Thursday morning after receiving the vaccine, which is recommended to travelers visiting sub-Saharan Africa, most of South America, and parts of Central American and the Caribbean …

Gore's death casts light on the heightened risk associated with the yellow fever vaccine and the over-60 demographic. Typical side effects of the vaccine include headaches, muscle pain, mild fever and soreness at the injection site …

However, the vaccinations can, in rare circumstances, cause more severe side effects, including allergic reactions and problems affecting the brain or organs …

The WHO reported that all cases of viscerotropic disease — a rare but dangerous side effect of yellow fever vaccinations where an illness similar to wild-type yellow fever proliferates in multiple organs — have occurred in primary vaccines, starting two to five days after vaccination."

Might Vaccine Reaction Rate Be as High as 1 in 10?

In the video above, Del Bigtree,13 an Emmy Award-winning producer of "The Doctors" talk show for six years, and one of the producers of the documentary, "Vaxxed," discusses vaccine safety, or rather the lack thereof.

In it, he recounts how, in 2010, the CDC hired a company to automate the federal vaccine adverse event reporting system (VAERS) in such a way that any potential vaccine reactions reported to doctors participating in the Harvard Pilgrim HMO would automatically be uploaded into the VAERS database.

Remarkably, preliminary data showed that out of 376,452 individuals given 45 different vaccines, 35,570 possible vaccine reactions were identified. This means nearly 1 in 10 people suffered a reaction after vaccination concerning enough to be reported, yet the official CDC mantra is that the risk for serious vaccine injury or death is 1 in 1 million.

Unfortunately, while the creation of VAERS in 1986 was an opportunity to get a firmer grasp of the number of potential vaccine reactions, injuries and deaths occurring after vaccinations given in the U.S., the CDC didn't follow through, and the project fell by the wayside.

Medical Errors Are the Third Leading Cause of Death in the US

While I've focused a lot of attention on vaccines and the necessity for educating yourself about their risks in this article, vaccines are by far not the only hazard presented by the medical industry. In fact, medical errors in general are the third leading cause of death, killing an estimated 250,000 Americans each year,14,15 an increase of about 25,000 people annually from data published in 2000.16

Side effects from drugs, taken as prescribed, account for the vast majority of iatrogenic deaths, but unnecessary surgeries, medication errors in hospitals, hospital-acquired infections and other medical errors occurring in hospitals also claim their fair share of lives.

Research17 published in 2013 estimated that preventable hospital errors kill 210,000 Americans each year — a figure that comes very close to the latest statistics. However, when deaths related to diagnostic errors, errors of omission, and failure to follow guidelines were included, the number skyrocketed to 440,000 preventable hospital deaths each year.

10 Tips to Avoid Medical Harm

How can you avoid becoming one of these statistics? Aside from educating yourself on the risks and benefits of vaccines, here are several additional suggestions:

Ask your doctor whether a recommended test and/or treatment is really necessary, and do your own homework — According to a report by the Institute of Medicine, an estimated 30 percent of all medical procedures, tests and medications may be unnecessary,18 any one of which can put you at risk for a potentially serious or lethal side effect.

An investigation19 by the Mayo Clinic published in 2013 also revealed between 40 and 78 percent of the medical testing, treatments and procedures you receive are of no benefit to you — or are actually harmful — as determined by clinical studies. To learn which tests and interventions may do more harm than good, browse through the Choosing Wisely website.20

Avoid hospitals unless absolutely necessary — According to 2011 statistics, 1 in 25 patients in the U.S. end up contracting some form of infection while in the hospital,21 and 205 Americans die from hospital-acquired infections each and every day.22

Do your due diligence before undergoing endoscopy — If you're having a colonoscopy or any other procedure using a flexible endoscope done, you can significantly reduce your risk of contracting an infection by asking the hospital or facility how the scope is cleaned, and which cleaning agent is used.

Some esophagoscopes and bronchoscopes have sterile sheaths with disposable air-water and biopsy channels, but many others do not, and must be cleaned between each use. If the hospital or clinic uses glutaraldehyde, or the brand name Cidex, cancel your appointment and go elsewhere.

About 80 percent of clinics use glutaraldehyde because it's a less expensive alternative; however, it does not do a good job of sterilizing the equipment. If they use peracetic acid, your likelihood of contracting an infection from a previous patient is slim.

To learn more about this, see my interview with David Lewis, Ph.D., in "How Improper Sterilization of Endoscopes Could Put Your Health at Risk."

Enlist a health care advocate — Once hospitalized, you're at risk for medical errors, so one of the best safeguards is to have someone there have someone there with you. It's important to have a personal advocate present to ask questions and take notes.

For every medication given in the hospital, ask questions such as: "What is this medication? What is it for? What's the dose?" Most people, doctors and nurses included, are more apt to go through that extra step of due diligence to make sure they're getting it right if they know they'll be questioned about it.

To learn more, listen to my interview with Dr. Andrew Saul in "What Hospitals Won't Tell You — Vital Strategies That Could Save Your Life," or pick up a copy of his book, "Hospitals and Health: Your Orthomolecular Guide to a Shorter Hospital Stay."

In it, he discusses the dangers of hospital stays, the type of patient that tends to get killed most frequently, and how you can protect your health and life in the event you have to be hospitalized. For example, reminding nurses and doctors to wash their hands and change gloves before touching you can go a long way toward avoiding contamination with potentially lethal microbes.

Do your own prep for surgery — If you or someone you know is scheduled for surgery, print out the WHO surgical safety checklist and implementation manual,23 which is part of the campaign "Safe Surgery Saves Lives." The checklist can be downloaded free of charge here. Print it out and bring it with you, as this can help you protect yourself, your family member or friend from preventable errors in care.

Know the most effective protocol for sepsis — Sepsis is a progressive disease process initiated by an aggressive, dysfunctional immune response to an infection in the bloodstream, which is why it's sometimes referred to as blood poisoning. Each year, an estimated 1 million Americans get sepsis24,25 and up to half of them die as a result.26,27,28

Symptoms of sepsis are often overlooked, even by health professionals, and without prompt treatment, the condition can be deadly.

Unfortunately, conventional treatments often fail, and most hospitals have yet to embrace the use of intravenous (IV) vitamin C, hydrocortisone and thiamine,29 a treatment developed by Dr. Paul Marik, which has been shown to reduce sepsis mortality from 40 to a mere 8.5 percent.30,31 Common signs and symptoms of sepsis to watch out for include:32

A high fever

Inability to keep fluids down

Rapid heartbeat; rapid, shallow breathing and/or shortness of breath

Lethargy and/or confusion

Slurred speech, often resembling intoxication

Should a few or all of these be present, seek immediate medical attention to rule out sepsis. Also inform the medical staff that you suspect sepsis, as time is of the essence when it comes to treatment, and urge them to use Marik's protocol (currently the standard of care for sepsis at Sentara Norfolk General Hospital, where Marik works). You can learn more about this protocol by following the hyperlink provided above.

Optimize your vitamin D instead of getting the flu vaccine — Research33,34 shows vitamin D optimization is a more effective flu prevention strategy than flu vaccination, reducing respiratory infections such as influenza by 50 percent in those with vitamin D blood levels below 10 ng/mL. People with higher vitamin D levels at baseline may reduce their risk by about 10 percent, which the researchers stated was about equal to the effect of flu vaccines.

Aside from vitamin D, loading up on vitamins B1 and C may go a long way toward keeping you healthy through the flu season and beyond. Influenza has also been successfully treated with high-dose vitamin C.35 Taking zinc lozenges at the first sign of a cold or flu can also be helpful.

Avoid antibiotics — Drugs are vastly overprescribed and misused, and this is particularly true for antibiotics. Avoid using them unless absolutely necessary, and remember they don't work for viral infections. Unnecessary use of antibiotics is one of the driving causes of antibiotic-resistant superbugs.

Turn a deaf ear to drug ads — While drug makers are required to inform consumers about potential side effects in their ads, they've perfected drug ad narration to make them less frightful.36

Avoid drugs, unless absolutely necessary — As mentioned, drugs — taken as prescribed — account for a majority of the 250,000 people who die from medical mistakes in the U.S. each year. A great many, if not most, diseases can be effectively addressed using simple lifestyle changes.

Key factors include diet, exercise and nonexercise movement, sleep and stress reduction. To investigate your options, you can search my database of tens of thousands of articles simply by entering your condition in the search engine.

Among the most lethal drugs right now are the opioids, which need to be used with extreme care and only in the short term. For treatment options, see "Treating Pain Without Drugs," and "Study Reveals Previously Unknown Mechanism Behind Acupuncture's Ability to Reduce Pain," which also provides a long list of other drug-free pain relief strategies.

Tip #21Make Magnesium a Priority

from http://articles.mercola.com/sites/articles/archive/2019/01/22/tips-to-avoid-medical-harm.aspx

source http://niapurenaturecom.weebly.com/blog/top-tips-to-avoid-pharmaceutical-injury